INHALE 1: A 26-week Primary Treatment Phase, with 26-week Extension, Open-label, Randomized Clinical Trial Evaluating the Efficacy and Safety of Afrezza® Versus Rapid-acting Insulin Analog Injections, Both in Combination with a Basal Insulin, in Pediatric Subjects with Type 1 or Type 2 Diabetes Mellitus
What is the goal of the study?
The primary objective of this study is to demonstrate that the efficacy of Afrezza is noninferior to rapid-acting insulin analog (RAA) injections, when both are in combination with a basal insulin, as measured by the change in glycated hemoglobin (HbA1c) from baseline to Week 26 in pediatric subjects ages 4 to 17 with type 1 or type 2 diabetes mellitus.
Who can participate in the study?
Please contact the study team listed below to learn more.